No Data
Scynexis Initiates Dosing in Phase 1 Trial of SCY-247
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
Express News | Scynexis Initiates Dosing in Phase 1 Trial of Scy-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
US Manufacturing Index Rises To 43, Highest Since 2020
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK) and SCYNEXIS (SCYX)
SCYNEXIS's Strong Financial Position and Strategic Advancements Drive Buy Rating
loading...
ok, just curious because it doesn't seem to have anything to do with IMPP. not use to seeing random thoughts in comments. thanks for explaining.
